Cost-effectiveness of once-daily single-inhaler triple therapy In COPD: The IMPACT Trial by Halpin, David M G
OR I G I N A L R E S E A R C H
Cost-Effectiveness Of Once-Daily Single-Inhaler
Triple Therapy In COPD: The IMPACT Trial
This article was published in the following Dove Press journal:
International Journal of Chronic Obstructive Pulmonary Disease
Afisi S Ismaila 1,2
Nancy Risebrough3
Melanie Schroeder 4
Dhvani Shah5
Alan Martin 6
Emma C Goodall 7
Kerigo Ndirangu5
Gerard Criner8
Mark Dransfield9
David MG Halpin10
MeiLan K Han11
David A Lomas12
1Value Evidence and Outcomes,
GlaxoSmithKline plc, Collegeville, PA,
USA; 2Department of Health Research
Methods, Evidence and Impact, McMaster
University, Hamilton, ON, Canada;
3ICON Health Economics, ICON plc,
Toronto, ON, Canada; 4Value Evidence
and Outcomes, GlaxoSmithKline plc,
Brentford, UK; 5ICON Health
Economics, ICON plc, New York, NY,
USA; 6Value Evidence and Outcomes,
GlaxoSmithKline plc, Uxbridge, UK;
7Health Economics and Outcomes
Research, GlaxoSmithKline plc,
Mississauga, ON, Canada; 8Lewis Katz
School of Medicine at Temple University,
Philadelphia, PA, USA; 9Division of
Pulmonary, Allergy, and Critical Care
Medicine, Lung Health Center, University
of Alabama at Birmingham, Birmingham,
AL, USA; 10Department of Respiratory
Medicine, Royal Devon and Exeter
Hospital, Exeter, UK; 11University of
Michigan, Pulmonary and Critical Care,
Ann Arbor, MI, USA; 12UCL Respiratory,
University College London, London, UK
Background: We assessed the cost-effectiveness of single-inhaler fluticasone furoate (FF)/
umeclidinium (UMEC)/vilanterol (VI) versus FF/VI or UMEC/VI from a Canadian public
healthcare perspective, incorporating data from the IMPACT trial in chronic obstructive
pulmonary disease (COPD) (NCT02164513).
Methods: Baseline inputs and treatment effects from IMPACT were populated into the
validated GALAXY-COPD disease progression model. Canadian unit costs and drug costs
(Canadian dollars [C$], 2017) were applied to healthcare resource utilization and treatments.
Future costs and health outcomes were discounted at 1.5% annually. Analyses were prob-
abilistic, and outputs included exacerbation rates, costs, and life years (LYs) and quality-
adjusted life years (QALYs) gained.
Results: Compared with FF/VI and UMEC/VI over a lifetime horizon, the analyses pre-
dicted that treatment with FF/UMEC/VI resulted in fewer moderate and severe exacerba-
tions, more LYs and more QALYs gained, with a small incremental cost. The base-case
incremental cost-effectiveness ratio (ICER) per QALY gained was C$18,989 (95% confi-
dence interval [CI]: C$14,665, C$25,753) versus FF/VI and C$13,776 (95% CI: C$9787, C
$19,448) versus UMEC/VI. FF/UMEC/VI remained cost-effective versus both FF/VI and
UMEC/VI in all sensitivity analyses, including in scenario analyses that considered different
intervention and comparator discontinuation rates, and treatment effects for subsequent
therapy.
Conclusion: Treatment with FF/UMEC/VI was predicted to improve outcomes and be a
cost-effective treatment option for patients with symptomatic COPD and a history of
exacerbations compared with FF/VI or UMEC/VI, in Canada.
Keywords: chronic obstructive pulmonary disease, cost-effectiveness, single-inhaler triple
therapy, quality-adjusted life years, Canada
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, progressive disease
characterized by persistent airflow limitation.1 Despite the availability of current
treatments, COPD is associated with substantial morbidity and mortality, and incurs
significant costs due to physician visits, hospitalizations and emergency room (ER)
visits.2 In Canada, COPD represents the second most common cause for hospital
admissions3 and was the fifth leading cause of death in 2016,4 resulting in high
healthcare resource utilization (HRU) and economic burden on the Canadian
healthcare system.3,5
Pharmacological therapy in COPD aims to reduce symptoms, improve exercise
tolerance and health status, and decrease exacerbation frequency.1 Guidelines from
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the Canadian Thoracic Society recommend a step-up to
triple therapy with an inhaled corticosteroid (ICS), a long-
acting muscarinic antagonist (LAMA), and a long-acting
β2-agonist (LABA) in patients who remain symptomatic
despite treatment with dual therapy (LAMA/LABA).6
Until recently, triple therapy could only be achieved via
the use of multiple inhalers. Though the cost-effectiveness
of this approach has been widely investigated (a cost-
effectiveness analysis of multiple-inhaler triple therapy
[MITT] with umeclidinium [UMEC] plus ICS/LABA has
recently been published),7 there are very few studies
exploring the cost-effectiveness of single-inhaler triple
therapy (SITT). As SITT is associated with improved
adherence compared with MITT,8 understanding its cost-
effectiveness may be important for patients, clinicians, and
healthcare payers.
Triple therapy incorporating an ICS (fluticasone furo-
ate [FF]), a LAMA (UMEC) and a LABA (vilanterol [VI])
administered in a single dry-powder inhaler (Trelegy
ELLIPTA) is the first SITT to be licensed for COPD
treatment in adults in Canada.9
IMPACT (InforMing the PAthway of COPD
Treatment; NCT02164513, GlaxoSmithKline plc. study
CTT116855)10 was a landmark phase III study that eval-
uated the relative benefits and risks of triple therapy with
FF/UMEC/VI (100/62.5/25 µg) compared with its compo-
nent molecules, FF/VI (100/25 µg) and UMEC/VI (62.5/
25 µg) in 10,355 symptomatic patients aged ≥40 years
with moderate-to-severe COPD and a history of exacerba-
tions. Treatment with FF/UMEC/VI reduced the annual
rate of moderate/severe COPD exacerbations, regardless
of eosinophil level, improved lung function, and improved
health-related quality of life (HRQoL) versus FF/VI or
UMEC/VI administered with the same delivery device at
the same doses.10 Additionally, FF/UMEC/VI significantly
decreased the annual rate of exacerbations leading to hos-
pitalization compared with UMEC/VI.10 All reports of
exacerbation events in the IMPACT trial were adjudicated
by an independent committee, unaware of the treatment
assignments.10
The IMPACT study results indicated that SITT with
FF/UMEC/VI may be the most appropriate treatment
option for patients with moderate-to-severe COPD who
are symptomatic according to COPD Assessment Test
(CAT) score and have experienced at least one exacerba-
tion in the past 12 months.10 We conducted a cost-effec-
tiveness analysis from a Canadian public healthcare payer
perspective to compare: (1) FF/UMEC/VI versus FF/VI;
and (2) FF/UMEC/VI versus UMEC/VI in the IMPACT
patient population.
Materials And Methods
Cost-Effectiveness Model
The current analysis was conducted using the GALAXY-
COPD disease progression model, which has been pre-
viously published and validated.11–13 The GALAXY
model incorporates associations between disease attri-
butes, progression and outcomes,11,14,15 represented by
linked-risk equations that predict disease progression in
terms of decline in forced expiratory volume in 1 s
(FEV1), exacerbation incidence, COPD symptoms, and
HRQoL, and the associated resource utilization, survival
and quality-adjusted life years (QALYs; Figure 1). The
linked-risk equations for clinical outcomes are based on
data from the Evaluation of COPD Longitudinally to
Identify Predictive Surrogate End-points (ECLIPSE)
study,16,17 with predictions of HRU based on the
Towards a Revolution in COPD Health (TORCH) study.18
Cost-effectiveness calculations were based on popula-
tion characteristics and clinical effects data from patients
enrolled in IMPACT, with application of Canadian cost
data to medication costs and predicted HRU.
Model Inputs
Patient Population
The study design, methods and results for IMPACT have
been published previously.10 All analyses were conducted
using the intent-to-treat (ITT) population (N=10,355). Since
baseline characteristics were similar across treatment arms,
pooled baseline characteristics across all three comparator
arms were used as baseline parameter inputs for each com-
parator in the model (Table 1). This ensured that all treat-
ment groups had the same starting values.
The risk equations in the GALAXY model included
some baseline values for data not collected in IMPACT,
including modified Medical Research Council (mMRC)
Dyspnea Scale, 6-min walk test (6MWT) and fibrinogen,
as covariates in the model. Values for these parameters
(Table 1) were estimated as follows: the proportion of
patients with CAT score ≥21 (from IMPACT) was
assumed to be the same as the proportion with mMRC
dyspnea score ≥2, based on published data26 and baseline
6MWT and fibrinogen were predicted using a risk equation
developed through analysis of ECLIPSE data16,17 (Online
Supplementary Tables S1 and S2).
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Treatment Effects
Treatment effects of FF/UMEC/VI in the IMPACT ITT
population were included as incremental effects relative to
each of the comparators (FF/VI and UMEC/VI) (Table 1),
and were assumed to continue until treatment discontinua-
tion. For this reason, predicted outcomes with FF/VI or
UMEC/VI, as reference treatments, appear the same in
both analyses.
Improvement in FEV1 predicts St George’s Respiratory
Questionnaire (SGRQ) and exacerbation treatment effects
in the model. Therefore, to avoid double counting or
under-prediction, the incremental magnitudes of SGRQ
and exacerbation treatment effects were adjusted and
entered into the model, calibrating to the 52-week trial
results from IMPACT. FEV1 treatment effect was entered
first, followed by exacerbations (moderate then severe)
and then SGRQ total scores. This ensured that the pre-
dicted clinical inputs, as far as possible, matched and
maintained the incremental benefits observed with FF/
UMEC/VI over FF/VI or UMEC/VI in the IMPACT data.
Treatment discontinuation rates were based on
IMPACT data and applied to the first year (Table 1). For
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Figure 1 Linked-risk equation model. Blue lines indicate the relationship between the central attributes in the different time periods. Orange lines indicate the relationship
between intermediate outcomes and exacerbations. Black lines indicate the relationship between the central attributes and the final health outcomes. Adapted from Briggs
AH, Baker T, Risebrough NA, et al (2017). Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation
of a Linked-Equations Cohort Model Med Decis Making, 37(4): 469–480. https://doi.org/10.1177/0272989X16653118. Copyright © 2017 by the authors. Reprinted by
permission of SAGE Publications, Inc.11 *Calculated (in mL) using the risk equation at 1 year and converted to FEV1% predicted based on the cohort profile.
Abbreviations: 6MWT, 6-min walk test; FEV1, forced expiratory volume in 1 s; LY, life year; QALY, quality-adjusted life year; RU, resource utilization; SGRQ, St. George’s
Respiratory Questionnaire.
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Table 1 Summary Of Model Inputs
Parameters Reference
Estimate
Probability
Distribution
Source
Baseline characteristics
Female, % 34 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Mean age, years 65.3 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Current smoker, % 35 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Any CV comorbidity, % 44 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Any other comorbidity, % 57 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
History of ≥1 exacerbation in the
previous year, %
100 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
BMI (kg/m2), %
BMI <21 17 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
BMI 21–30 58 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
BMI >30 25 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Dyspnea, %
None 1.7 Fixed Derived from a risk equation
Several days/week 32.9 Fixed Derived from a risk equation
Most days/week 65.4 Fixed Derived from a risk equation
Cough or sputum, most days/
week, %
52.2 Fixed Derived from a risk equation
Exacerbations in prior year
(mean), n
Total 1.71 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Moderate 1.41 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Severe 0.30 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Starting FEV1% predicted 45.5 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Starting FEV1 predicted by the
GALAXY model, mL
1215.3 Fixed Based on FEV1% reported in IMPACT and formulae based in ECLIPSE to
back calculate the starting FEV1 value
Height, cm 167.5 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
mMRC dyspnea score ≥2, % 37 Fixed % with CAT score ≥21 from IMPACT considered equivalent; IMPACT
Trial Supplementary Materials (GSK, 2017)
Fibrinogen, μg/dL 477.5 Fixed Not available from IMPACT, derived from a risk equation
6MWT, m 365.8 Fixed Not available from IMPACT, derived from a risk equation
Mean starting SGRQ total score 50.7 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Resulting HRQoL utility value 0.654 Fixed Calculated from SGRQ-C score by algorithm19
Treatment effects
FF/UMEC/VI versus FF/VI
Difference FEV1 incremental
change from baseline, mL
97 Normal
(SE=6.10)
IMPACT Trial Supplementary Materials (GSK, 2017)
(Continued)
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Table 1 (Continued).
Parameters Reference
Estimate
Probability
Distribution
Source
Difference SGRQ total score
change from baseline
−1.8 Normal
(SE=0.34)
IMPACT Trial Supplementary Materials (GSK, 2017), converted to
SGRQ-C
Moderate exacerbation
reduction, ratio
0.84 Log normal
(SE=0.03)
IMPACT Trial Supplementary Materials (GSK, 2017)
Severe exacerbation reduction,
ratio
0.87 Log normal
(SE=0.06)
IMPACT Trial Supplementary Materials (GSK, 2017)
FF/UMEC/VI versus UMEC/VI
Difference FEV1 incremental
change from baseline, mL
54 Normal
(SE=7.60)
IMPACT Trial Supplementary Materials (GSK, 2017)
Difference SGRQ total score
change from baseline
−1.8 Normal
(SE=0.42)
IMPACT Trial Supplementary Materials (GSK, 2017), converted to
SGRQ-C
Moderate exacerbation
reduction, ratio
0.77 Log normal
(SE=0.03)
IMPACT Trial Supplementary Materials (GSK, 2017)
Severe exacerbation reduction,
ratio
0.66 Log normal
(SE=0.06)
IMPACT Trial Supplementary Materials (GSK, 2017)
Treatment discontinuation at 52 weeks
FF/UMEC/VI 18.3% Beta (758/4151) IMPACT Trial Supplementary Materials (GSK, 2017)
FF/VI 25.2% Beta (1040/
4134)
IMPACT Trial Supplementary Materials (GSK, 2017)
UMEC/VI 27.3% Beta (566/2070) IMPACT Trial Supplementary Materials (GSK, 2017)
Drug costs Cost per day
FF/UMEC/VI (100/62.5/25 μg)
(Trelegy ELLIPTA)
C$4.41 Fixed Assume same as price for FF/VI + UMEC
UMEC (62.5 μg) (Incruse
ELLIPTA)
C$1.67 Fixed ODB, 201720
FF/VI (100/25 μg) (Breo ELLIPTA) C$2.74 Fixed ODB, 201720
UMEC/VI (62.5/25 μg) (Anoro
ELLIPTA)
C$2.70 Fixed ODB, 201720
Subsequent treatment cost
Average weighted cost of all
treatment classes
C$4.29 Fixed Average cost weighted by Canadian prescription utilization in regimen
class (based on IMS data)21
Outpatient medication
Cost of moderate exacerbations C$7.59 Fixed Calculation based on ODB, 201720
Rescue medication Cost per day
Salbutamol (Ventolin DISKUS) C$0.03 Fixed ODB, 201720
Occasions of rescue medication use per day
FF/UMEC/VI 1.75 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
(Continued)
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subsequent years, in the base case, discontinuation rates
were assumed to be the same as the first year for all
treatments (18.3% for FF/UMEC/VI, 25.2% for FF/VI
and 27.3% for UMEC/VI).
Utilities
Model-predicted SGRQ for COPD patients (SGRQ-C)
scores were translated into SGRQ total score and then
into an annual utility value using a published algorithm
for converting SGRQ to EQ-5D-3L index scores,19 as
follows:
EQ-5D-3L ¼ 0:9617 0:0013 SGRQ total
0:0001 SGRQ total2 þ 0:0231 male:
Costs
The study was conducted from the perspective of the
Canadian public healthcare payer and therefore included
only direct medical costs, in alignment with Canadian
Agency for Drugs and Technology in Health (CADTH)
guidelines for economic evaluations.27 Health service
costs were estimated using unit costs from Canadian refer-
ence price lists (in Canadian dollars [C$]), inflated to 2017
equivalents where necessary, and applied to resource uti-
lization counts for hospital days, ER visits and physician
visits predicted by the model (Table 1). Drug costs were
obtained from the Ontario Drug Benefit (ODB) Formulary,
201720 using dose, pack size and cost per pack (C$132.20,
C$82.20 and C$81.00 for FF/UMEC/VI, FF/VI and
UMEC/VI, respectively) to calculate the cost per daily
dose. As the list price of FF/UMEC/VI (100/62.5/25 μg)
was not available at the time of this analysis, the price of
FF/UMEC/VI was assumed to be equal to the sum of the
UMEC (C$50.00; 62.5 μg) and FF/VI (C$82.20; 100/25
μg) pack costs. Subsequent therapy cost was based on the
four most common classes of treatments taken after dis-
continuation in IMPACT, pooled across all treatment arms
(Table S3). The average daily cost of subsequent treatment
was estimated at C$4.29, based on drug costs20 weighted
by Canadian prescription utilization data for each treat-
ment class.21 Treatment costs for moderate exacerbations
and use of salbutamol rescue medication were also
Table 1 (Continued).
Parameters Reference
Estimate
Probability
Distribution
Source
FF/VI 2.03 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
UMEC/VI 2.05 Fixed IMPACT Trial Supplementary Materials (GSK, 2017)
Hospital costs
Cost per day in ICU C$3843.40 Fixed CIHI, 201622 OHIP, 201623 Statistics Canada, 201724
Cost per day in general ward C$1256.30 Fixed CIHI, 201622 Statistics Canada, 201724
ER visit C$76.90 Fixed OHIP, 201623
Hospital outpatient visit – initial
visit
C$157.00 Fixed OHIP, 201623
Physician costs
Day(/night) home visit# C$45.15 Fixed OHIP, 201623
Visit to physician’s office (family
physician)
C$77.20 Fixed OHIP, 201623
Telephone consultation¶ C$9.30 Fixed OHIP, 201623 Statistics Canada, 201724 Payscale, 201725
Notes: The IMPACT Trial Supplementary Materials are GlaxoSmithKline plc. internal data on file (Nov/Dec 2017). #The model assumes the same cost for home
consultations whether they occur during “day” or “night” hours; OHIP 2016 schedule reports billing rates current in 2017. ¶The cost of a telephone call is based on
assuming the interaction is 10 min in length and a nurse (registered nurse hourly wage C$33.01) will take the call 60% of the time and a physician the remaining 40%.
Physician code H101 (C$15.00) was selected as a substitute value since there is no appropriate code for a telephone call between a patient and physician.
Abbreviations: 6MWT, 6-min walk test; BMI, body mass index; CAT, COPD Assessment Test; CIHI, Canadian Institute for Health Information; CV, cardiovascular; C$,
Canadian dollars; ER, emergency room; FEV1, forced expiratory volume in 1 s; FF, fluticasone furoate; HRQoL, health-related quality of life; ICU, intensive care unit; IMS, IMS
Brogan ODB RxDynamics Database; mMRC, modified Medical Research Council; ODB, Ontario Drug Benefit; OHIP, Ontario Health Insurance Program; SE, standard error;
SGRQ, St. George’s Respiratory Questionnaire; SGRQ-C, St. George’s Respiratory Questionnaire for COPD patients; UMEC, umeclidinium; VI, vilanterol.
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included in the analysis (see Online Supplementary
Appendix).
Base-Case Settings And Assumptions
A lifetime horizon was used for the base-case analysis.
Costs and health outcomes were discounted at 1.5% per
annum, consistent with CADTH guidelines for economic
evaluations.27 It was assumed that patients who discontin-
ued their initial treatment experienced the same efficacy as
the reference treatment (FF/VI or UMEC/VI) for the
remainder of the analysis. All analyses were probabilistic,
conducted by assigning distributions to input parameters
and randomly sampling from these distributions over 5000
Monte Carlo simulations.
Model Outputs
The model outputs were total moderate and severe exacer-
bations, costs (drug-related and non-drug-related), QALYs
and life years (LYs; undiscounted) gained, and incremental
cost-effectiveness ratio (ICER) per QALY gained.
Sensitivity Analyses
Sensitivity analyses were conducted to test the robust-
ness of the base-case results when parameters were not
available from IMPACT (fibrinogen, 6MWT, mMRC
dyspnea score). Cost, efficacy and utility inputs were
varied to the upper and lower bounds of the range
around baseline estimates (fibrinogen, 472.8–482.1 μg/
dL; 6MWT, 360.4–371.2 m; mMRC dyspnea score ≥2,
27.8–46.3%). Baseline fibrinogen and 6MWT limits
were varied to 95% confidence limits approximated
using ECLIPSE data, and ±25% limits were used for
mMRC dyspnea score, and hospital and physician costs.
As estimates of HRQoL experienced by patients can
vary, the sensitivity analysis also explored the impact
of higher (+10%) utility values, to be comparable with
those reported in the literature.28
Scenario analyses were performed with alternative
model settings or assumptions to aid understanding of
model drivers, and to provide estimates of ICERs
under plausible, alternative real-world situations. The
scenarios tested were: shorter time horizons, 0% and
3% discount rates, alternate background exacerbation
rates, 0% treatment discontinuation for subsequent
years, different treatment effects and costs for
subsequent treatments, and replacement of FF/VI or
UMEC/VI cost with a Canada-specific utilization-
weighted cost for all ICS/LABAs or LAMA/LABAs,
respectively.
Results
Base Case
Over a lifetime horizon, FF/UMEC/VI provided an additional
0.1388 LYs (9.0524 versus 8.9136) and 0.1371 QALYs
(5.0431 versus 4.9060) for an additional cost of C$2604 per
patient, compared with ICS/LABA therapy, FF/VI (Table 2).
Patients taking FF/UMEC/VI had fewer total exacerbations
(incremental difference, 0.1050; 6% reduction) per-patient
per-year (PPPY) compared with those taking FF/VI. Across
all simulations, FF/UMEC/VI showed higher QALYs but
was costlier comparedwith FF/VI (Figure 2A). The estimated
ICERwas C$18,989/QALY (95% CI: C$14,665, C$25,753),
and at a willingness-to-pay threshold of C$50,000/QALY, the
probability that FF/UMEC/VI was cost-effective versus FF/
VI was 100% (Figure 3).
Compared with the LAMA/LABA therapy UMEC/VI,
FF/UMEC/VI provided an additional 0.1177 LYs (9.0258
versus 8.9081) and 0.1282 QALYs (5.0352 versus 4.9070),
at an additional cost of C$1766 per patient (Table 3).
Patients receiving FF/UMEC/VI also had 10% fewer
total PPPY exacerbations (incremental difference, 0.1714;
10% reduction) compared with those treated with UMEC/
VI. FF/UMEC/VI showed higher QALYs and costs com-
pared with UMEC/VI across all simulations (Figure 4A).
The estimated ICER was C$13,776/QALY (95% CI: C
$9787, C$19,448), and at a willingness-to-pay threshold
of C$50,000/QALY, the probability that FF/UMEC/VI was
cost-effective versus UMEC/VI was 100% (Figure 5).
Sensitivity Analyses
Across all sensitivity analyses, FF/UMEC/VI remained
cost-effective versus both FF/VI and UMEC/VI at a will-
ingness-to-pay threshold of C$50,000/QALY, with ICERs
ranging from C$17,220/QALY to C$20,141/QALY versus
FF/VI (Figure 2B; Table S4) and C$12,508/QALY to C
$13,933/QALY versus UMEC/VI (Figure 4B; Table S5).
For model parameters derived from risk equations or ana-
logous IMPACT data (baseline fibrinogen, 6MWT and
mMRC dyspnea score), sensitivity analyses showed only
a minimal impact on the ICER when comparing to either
FF/VI (−1 to 0% variation versus the base case) or UMEC/
VI (0 to 1% variation versus the base case). Varying
physician visit and hospital costs by ±25% also showed
little variation (−7 to 6% versus FF/VI and −1 to 1%
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versus UMEC/VI). The greatest impact was observed by
varying the predicted utility value in each cycle by 10%,
which resulted in a 9% ICER decrease versus both dual
therapies.
Results of the scenario analyses were also consistent
with the base case, with FF/UMEC/VI remaining cost-
effective versus FF/VI across all scenarios (Figure 2B;
Table S4): the ICER ranged from dominant to C$23,800/
QALY. This was also the case versus UMEC/VI
(Figure 4B; Table S5), with the ICER ranging from domi-
nant to C$21,818/QALY. In the two scenarios run for
treatment discontinuation inputs, a 2% reduction in the
ICER versus both comparators was observed when dis-
continuation was assumed as 0% after the first year. When
the treatment effect for subsequent therapy was assumed to
be that of FF/UMEC/VI, a 21% increase in the ICER was
observed versus FF/VI (C$23,025/QALY) and a 44%
increase in the ICER was observed versus UMEC/VI (C
$19,880/QALY).
Varying the background exacerbation rate by 50% (of
that predicted by the risk equation) resulted in a 10%
increase in the ICER versus FF/VI and a 58% increase
versus UMEC/VI. When the background exacerbation rate
was increased by 200% (ie to approximately three exacer-
bations PPPY), FF/UMEC/VI was a dominant (more
effective and at lower costs) option versus both
comparators.
Changing the time horizon showed a substantial impact
only when reduced to 5 years, resulting in a 25% increase
in the ICER compared with the lifetime horizon versus FF/
VI (C$23,800/QALY) and a 26% increase in the ICER
compared with the lifetime horizon versus UMEC/VI (C
$17,420/QALY). Variation in the ICER relative to the base
case was minimal with a 10-year time horizon versus both
comparators (3% change [C$19,551/QALY] versus FF/VI
and 1% change [C$13,946/QALY] versus UMEC/VI).
Discussion
This cost-effectiveness study from the Canadian public
healthcare payer perspective used the GALAXY model
to predict disease progression and outcomes, based on
pooled patient characteristics and relative treatment effects
for FF/UMEC/VI versus FF/VI or UMEC/VI from
IMPACT.10 Treatment with FF/UMEC/VI resulted in
Table 2 Cumulative And Incremental Lifetime Outcomes Of FF/UMEC/VI Versus FF/VI
FF/UMEC/VI FF/VI Difference
Cumulative exacerbations
Moderate exacerbations 10.6200 11.2337 −0.6136
Severe exacerbations 3.5326 3.6314 −0.0988
Total exacerbations (moderate and severe) 14.1526 14.8650 −0.7124
Moderate exacerbations PPPY 1.1728 1.2605 −0.0878
Severe exacerbations PPPY 0.3884 0.4056 −0.0172
Total exacerbations PPPY 1.5611 1.6661 −0.1050
Health outcomes
Accumulated LYs (undiscounted) 9.0524 8.9136 0.1388
Accumulated QALYs 5.0431 4.9060 0.1371
Costs
Drug costs C$13,387 C$11,461 C$1926
Total non-drug costs C$53,750 C$53,072 C$678
Hospital (ICU and ward) costs C$52,506 C$51,835 C$672
Outpatient/ER costs C$651 C$646 C$5.38
Physician visit costs C$592 C$591 C$0.96
Accumulated costs total C$67,137 C$64,533 C$2604
Incremental results
Incremental costs (95% CI) C$2604 (C$1980, C$3285)
Incremental LYs (95% CI) undiscounted 0.1388 (0.068, 0.207)
Incremental QALYs (95% CI) 0.1371 (0.092, 0.182)
ICER/QALY gained (95% CI) C$18,989 (C$14,665, C$25,753)
Abbreviations: CI, confidence interval; C$, Canadian dollars; ER, emergency room; FF, fluticasone furoate; ICER, incremental cost-effectiveness ratio; ICU, intensive care
unit; LY, life year; QALY, quality-adjusted life year; PPPY, per patient per year; UMEC, umeclidinium; VI, vilanterol.
Ismaila et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Chronic Obstructive Pulmonary Disease 2019:142688
increased clinical benefit and health outcomes (reduction
in exacerbations, gains in LYs and QALYs) with a mod-
erate cost increment. Costs were greater with FF/UMEC/
VI, mainly due to increased medication costs relative to
both dual therapies. Compared with UMEC/VI, these were
offset by lower non-drug costs with FF/UMEC/VI due to
fewer severe exacerbations and associated hospital days.
Non-drug costs were higher for FF/UMEC/VI versus FF/
VI, partly because the exacerbation benefit for FF/UMEC/
VI versus FF/VI was less than that versus UMEC/VI, but
also because the greater FEV1 benefit observed with FF/
UMEC/VI led to improved survival and thus a higher
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Baseline fibrinogen lower CI
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B
Baseline fibrinogen upper CI
Baseline 6MWT lower CI
Baseline 6MWT upper CI
Baseline mMRC dyspnoea score ≥2 –25%
Baseline mMRC dyspnoea score ≥2 +25%
All hospital costs: –25%
All hospital costs: +25%
All physician visits: –25%
All physician visits: +25%
Predicted utility value in each cycle increased by 10% 
5-year time horizon
10-year time horizon
Discount rate: 0%
Discount rate: 3% 
Background exacerbation rate at 50%
Background exacerbation rate at 200%
Treatment discontinuation for subsequent years: 0%
Set treatment effect for subsequent therapies same as SITT
For subsequent therapies* – Highest cost in each treatment class
For subsequent therapies* – Lowest cost in each treatment class
For subsequent therapies, generic pricing for FP/SAL DPI (75% of current cost in weighted calculation)
For subsequent therapies, generic pricing for FP/SAL DPI (35% of current cost in weighted calculation)
Use utilization weighted cost of all ICS/LABAs replaced for cost of FF/VI
Use utilization weighted cost of ICS/LABAs indicated for COPD replaced for cost of FF/VI
Base case: C$18989 
ICER/QALY gained, C$
Dominant
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Figure 2 Incremental cost-effectiveness plane for FF/UMEC/VI versus FF/VI (A), and tornado plot of sensitivity and scenario analyses (B). *Assume 100% market share of
product.
Abbreviations: 6MWT, 6-min walk test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; C$, Canadian dollars; DPI, dry-powder inhaler; FF,
fluticasone furoate; FP, fluticasone propionate; ICER, incremental cost-effectiveness ratio; ICS, inhaled corticosteroid; ITT, intent to treat; LABA, long-acting β2-agonist;
mMRC, modified Medical Research Council; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SAL, salmeterol; SITT, single-inhaler triple therapy; UMEC,
umeclidinium; VI, vilanterol.
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overall lifetime cost, due to prolonged utilization of
healthcare resources. These analyses suggest that the
higher acquisition cost of FF/UMEC/VI could be partially
offset by savings elsewhere in the health service. Over a
lifetime horizon, the probability that treatment with FF/
UMEC/VI would be cost-effective versus UMEC/VI or
FF/VI was 100% at a willingness-to-pay threshold of C
$50,000/QALY.
FF/UMEC/VI remained cost-effective across all sensi-
tivity and scenario analyses, suggesting that the results are
robust when considering a number of uncertainties. In
particular, cost-effectiveness was maintained in scenarios
with higher and lower exacerbation rates, an important
observation in the context of real-world populations
where rates may be variable. For example, annual exacer-
bation rates in North American populations have been
reported to range widely from 0.47 to 4.22.29 It is also
important to note that the baseline values for estimated
parameters such as 6MWT, fibrinogen level, and mMRC
dyspnea score had a minimal influence on cost-effective-
ness. Here, the mMRC dyspnea score was estimated in
line with patient CAT scores from the IMPACT trial and,
although there is more than one view regarding the equiva-
lence of these parameters,1,26 the negligible deviation
noted in sensitivity analyses when varying mMRC dys-
pnea score by ±25% suggests that the results would not
have been significantly different had alternative equiva-
lence cut-offs been used.
Data on long-term discontinuation rates were not avail-
able and the assumption in the base case that
Table 3 Cumulative And Incremental Lifetime Outcomes Of FF/UMEC/VI Versus FF/VI
FF/UMEC/VI UMEC/VI Difference
Cumulative exacerbations
Moderate exacerbations 10.2638 11.2357 −0.9719
Severe exacerbations 3.2631 3.6314 −0.3683
Total exacerbations (moderate and severe) 13.5269 14.8671 −1.3402
Moderate exacerbations PPPY 1.1364 1.2615 −0.1251
Severe exacerbations PPPY 0.3593 0.4056 −0.0464
Total exacerbations PPPY 1.4957 1.6671 −0.1714
Health outcomes
Accumulated LYs (undiscounted) 9.0258 8.9081 0.1177
Accumulated QALYs 5.0352 4.9070 0.1282
Costs
Drug costs C$13,346 C$11,519 C$1827
Total non-drug costs C$53,065 C$53,126 −C$61
Hospital (ICU and ward) costs C$51,830 C$51,887 −C$58
Outpatient/ER costs C$645 C$646 −C$0.72
Physician visit costs C$589 C$592 −C$2.67
Accumulated costs total C$66,411 C$64,644 C$1766
Incremental results
Incremental costs (95% CI) C$1766 (C$1167, C$2336)
Incremental LYs (95% CI) undiscounted 0.1177 (0.048, 0.186)
Incremental QALYs (95% CI) 0.1282 (0.081, 0.177)
ICER/QALY gained (95% CI) C$13,776 (C$9787, C$19,448)
Abbreviations: CI, confidence interval; C$, Canadian dollars; ER, emergency room; FF, fluticasone furoate; ICER, incremental cost-effectiveness ratio; ICU, intensive care
unit; LY, life year; QALY, quality-adjusted life year; PPPY, per patient per year; UMEC, umeclidinium; VI, vilanterol.
Figure 3 Net benefit acceptability curves for FF/UMEC/VI versus FF/VI.
Abbreviations: C$, Canadian dollars; FF, fluticasone furoate; QALY, quality-
adjusted life year; UMEC, umeclidinium; VI, vilanterol.
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discontinuation rates for FF/UMEC/VI in the first year
were maintained in subsequent years is probably an over-
estimate. We therefore tested alternative assumptions in
scenario analyses. Against both comparators, a 2% reduc-
tion in the ICER was observed when the discontinuation
rate was set to 0% in subsequent years, since maintaining
the relative treatment effect for FF/UMEC/VI for the
treatment duration increased the incremental LYs and
QALYs. However, the impact of discontinuation on treat-
ment outcomes and cost-effectiveness is heavily influ-
enced by the assumed effect of subsequent therapy and
its costs. In the base case, treatment effect was assumed to
be similar to the reference treatment but, in IMPACT, dual
therapy had higher discontinuation rates than FF/UMEC/
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All physician visits: –25%
All physician visits: +25%
Predicted utility value in each cycle increased by 10% 
5-year time horizon
10-year time horizon
Discount rate: 0%
Discount rate: 3% 
Background exacerbation rate at 50%
Background exacerbation rate at 200%
Treatment discontinuation for subsequent years: 0%
Set treatment effect for subsequent therapies same as SITT
For subsequent therapies* – Highest cost in each treatment class
For subsequent therapies* – Lowest cost in each treatment class
For subsequent therapies, generic pricing for FP/SAL DPI (75% of current cost in weighted calculation)
For subsequent therapies, generic pricing for FP/SAL DPI (35% of current cost in weighted calculation)
Use utilization weighted cost of all LAMA/LABAs replaced for cost of UMEC/VI
Base case: C$13776
ICER/QALY gained, C$
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Figure 4 Incremental cost-effectiveness plane for FF/UMEC/VI versus UMEC/VI (A), and tornado plot of sensitivity and scenario analyses (B). *Assume 100% market share
of product.
Abbreviations: 6MWT, 6-min walk test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; C$, Canadian dollars; DPI, dry-powder inhaler; FF,
fluticasone furoate; FP, fluticasone propionate; ICER, incremental cost-effectiveness ratio; ITT, intent to treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic
antagonist; mMRC, modified Medical Research Council; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; SAL, salmeterol; SITT, single-inhaler triple
therapy; UMEC, umeclidinium; VI, vilanterol.
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VI,10 and most of the patients who discontinued any treat-
ment subsequently received triple therapy [data on file].
Thus, it is clinically plausible that patients who discontin-
ued may have derived greater benefit with subsequent
therapy than was assumed in the base case analysis,
which would decrease the incremental LYs and QALYs
gained for FF/UMEC/VI versus FF/VI or UMEC/VI. This
was tested in the scenario analysis where the effect of
subsequent therapy was assumed to be similar to FF/
UMEC/VI; ICERs increased versus both FF/VI (21%)
and UMEC/VI (44%) but FF/UMEC/VI remained cost-
effective.
It should be noted that this analysis did not examine the
effects of baseline eosinophil levels on cost-effectiveness
of treatment, as the annual rate of moderate or severe
exacerbations was lower with triple therapy than dual
therapy regardless of eosinophil level in the prespecified
IMPACT analysis. Furthermore, Canadian guidelines do
not currently consider eosinophil count in their
recommendations.6 While FF/UMEC/VI was associated
with clinical benefit irrespective of baseline eosinophil
count (<150 or ≥150 cells/µL) in the IMPACT trial,10
discussions surrounding the most appropriate cut-off
points for eosinophil count analyses are still evolving
and warrant further investigation before baseline eosino-
phil count can be confidently incorporated into cost-effec-
tiveness models.
Currently, there is little evidence available evaluating
the pharmacoeconomic value of inhaled triple therapy for
COPD maintenance in Canada. Although several other
models are available for COPD economic analysis, these
are structured around disease “states” typically described
in terms of predicted FEV1 and, only in some cases,
exacerbations.13,30–34 The advantage of the GALAXY
model for estimating cost-effectiveness is that it incorpo-
rates a broad range of disease attributes, including patient
baseline characteristics, exacerbation frequency, symptom
frequency, and exercise capacity, all of which can influ-
ence long-term outcomes.11 This better encompasses
COPD’s multifactorial nature.35,36 Using IMPACT data,10
which evaluated effects of all three comparators over 52
weeks, was another advantage of this analysis; this is the
same duration as the cycle length used in the GALAXY
model11 and provided a strong basis for extrapolation
beyond the first year. Additionally, using direct evidence
from the large, landmark IMPACT trial ensured the results
were not subject to the uncertainties introduced by includ-
ing treatment effects from differing populations, as they
would have been in a network meta-analysis.
There are some limitations to this study that should be
considered when interpreting its results. Firstly, it must be
noted that pneumonia events are not explicitly modeled in
GALAXY, although COPD-related HRU (including that
related to pneumonia) is predicted by the risk equations.
Although a recent analysis of IMPACT data demonstrated a
favorable benefit/risk profile for FF/UMEC/VI versus FF/VI
or UMEC/VI when considering the risk of pneumonia and
reduction in exacerbations as a composite outcome,37 expli-
cit exploration of the impact of pneumonia should be con-
sidered in future health economic analyses.
Secondly, it is important to clarify that the baseline
utility value specific to the Canadian population was una-
vailable for this analysis, and it may have differed from the
model-predicted value. Sensitivity analyses that repre-
sented a higher population baseline value by increasing
the utility value by 10% in each model cycle, however, did
not change the analysis conclusions, indicating that base-
line utility was not a model driver.
Thirdly, due to COPD’s chronic nature, a lifetime horizon
was used for the base case; however, considering shorter
timeframes may also be appropriate, partly because disconti-
nuation rates, like those observed in IMPACT,10 suggest that
a high proportion of patients receive alternative therapies in
the longer term. Analysis of real-world evidence may be
prudent to gain a deeper understanding of these treatment
patterns. Scenario analyses incorporating 5- and 10-year time
horizons were generally consistent with the base-case results;
there was minimal variation in the ICER with a 10-year time
horizon. FF/UMEC/VI also remained cost-effective versus
FF/VI or UMEC/VI when the time horizon was reduced to 5
years, although the ICER increased by 25% and 26% versus
FF/VI and UMEC/VI, respectively, compared with the base
Figure 5 Net benefit acceptability curves for FF/UMEC/VI versus UMEC/VI.
Abbreviations: C$, Canadian dollars; FF, fluticasone furoate; QALY, quality-
adjusted life year; UMEC, umeclidinium; VI, vilanterol.
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case. This suggests that not all health effects and cost con-
sequences were captured within this short timeframe.
Additionally, as the ELLIPTA inhaler was used to admin-
ister treatment in all three study arms of the IMPACT trial (a
key strength of its design), it was not possible to evaluate the
impact of single versus multiple inhalers or once-daily versus
more frequent dosing on treatment adherence, and so this
aspect of effectiveness could not be incorporated into the
economic model. SITT may lead to improved patient satisfac-
tion and adherence, and therefore potentially improved effec-
tiveness, versus MITT: number of inhalers has recently been
demonstrated as a driver of choice for COPD treatment.38 This
is an important consideration in real-world scenarios and a
future economic evaluation of SITT versus MITT, incorporat-
ing the impact of differential treatment adherence, is war-
ranted. FF/UMEC/VI is the first SITT approved for long-
term, COPD maintenance therapy in Canada, in patients
whose symptoms are not adequately controlled by a combina-
tion of ICS and LABA. FF/UMEC/VI enables patients to
benefit from maintenance therapy with ICS/LAMA/LABA
delivered in a single, once-daily inhalation.
Finally, the Canadian list price of FF/UMEC/VI was not
available at the time of these analyses and so the price was set
to equal the sum of the respective prices for UMEC and FF/
VI. Any reduction in the price of FF/UMEC/VI relative to the
sum of its components may lead to a more favorable ICER
compared with the results currently presented.
This study was from the perspective of the public
healthcare payer in Canada only, and the cost-effectiveness
of triple therapy with FF/UMEC/VI for COPD may differ
in other regions and countries. However, a UK-based
economic evaluation of FULFIL data using the
GALAXY model found FF/UMEC/VI to be a cost-effec-
tive option when compared with another dual therapy,
budesonide/formoterol, for the treatment of symptomatic
COPD.39 These results suggest that FF/UMEC/VI could
be a cost-effective option across a variety of payer systems
internationally, although confirmatory research in more
countries is required.
Conclusion
FF/UMEC/VI is predicted to be cost-effective in Canada for
the treatment of patients with symptomatic COPD and a
history of exacerbations. FF/UMEC/VI was more effective
than FF/VI or UMEC/VI, resulting in improved health out-
comes versus both comparators. Although the cost of FF/
UMEC/VI was higher than that of FF/VI or UMEC/VI, the
finding that FF/UMEC/VI was cost-effective versus both
comparators over a lifetime horizon, and in numerous sensi-
tivity and scenario analyses, indicates that this may be an
appropriate investment of health service funds in Canada.
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